Literature DB >> 12842433

Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates.

Julia Lanciotti1, Antonius Song, John Doukas, Barbara Sosnowski, Glenn Pierce, Richard Gregory, Samuel Wadsworth, Catherine O'Riordan.   

Abstract

Bifunctional PEG (polyethylene glycol) molecules provide a novel approach to retargeting viral vectors without the need to genetically modify the vector. In a previous report we showed that modification of the viral capsid by the addition of a peptide with binding preference for differentiated ciliated airway epithelia allowed gene delivery to those cells by a novel entry pathway. Here we demonstrate further the versatility of this method by coupling a protein, FGF2, to the surface of an adenovirus (Ad). This modification results in the elimination of the endogenous tropism of the virus and confers upon the virus a novel route of entry. Adenoviral vectors modified by the addition of FGF2 show enhanced efficiency of transduction of the ovarian cancer cell line SKOV3.ip1. This enhancement in transduction is dependent on the binding of the coupled FGF2 to its high-affinity receptor and is independent of coxsackie and adenovirus viral receptors. In an intraperitoneal model of ovarian cancer, Ad/PEG/FGF2 generates increased transgene expression in tumor tissue compared to unmodified Ad. Furthermore, polymer modification of adenovirus vectors results in reduced localization of adenovirus to nontarget tissues and a marked decrease in Th1 and Th2 T cell responses. In conclusion, the approach described here may lead to the development of a gene therapy vector capable of targeting a therapeutic gene to diseased cells, while minimizing toxicity and expression in other tissues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842433     DOI: 10.1016/s1525-0016(03)00139-4

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  34 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

2.  Gene transfer: Bax to the future for cancer therapy.

Authors:  N R Lemoine; I A McNeish
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

Review 3.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

4.  Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.

Authors:  Zhengming Xiong; Zhen Cheng; Xianzhong Zhang; Manish Patel; Joseph C Wu; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-01       Impact factor: 10.057

Review 5.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

6.  Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

Authors:  L Pereboeva; S Komarova; J Roth; S Ponnazhagan; D T Curiel
Journal:  Gene Ther       Date:  2007-01-25       Impact factor: 5.250

Review 7.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

Review 8.  Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems.

Authors:  Sabine Boeckle; Ernst Wagner
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

Review 9.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

Review 10.  The challenge for gene therapy: innate immune response to adenoviruses.

Authors:  Bart Thaci; Ilya V Ulasov; Derek A Wainwright; Maciej S Lesniak
Journal:  Oncotarget       Date:  2011-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.